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Background/aim: Systemic lupus erythematosus (SLE) is an autoimmune disease with a variety of organ/system involvement.
Respiratory system involvement is common in these patients and usually manifests itself by disorders of the lung parenchyma, pleura,
pulmonary vasculature or diaphragm. In this study, we sought to determine the frequency of interstitial lung disease (ILD) in patients
with SLE and associated risk factors.
Materials and methods: Three hundred randomly chosen patients with SLE were included. Chest x-ray (CXR), lung spirometry and
carbon monoxide diffusion test (DLCO) were performed. High-resolution thorax computed tomography (HRCT) was performed for a
definite diagnosis of ILD.
Results: Of 300 patients, 16% had ILD. At the start of the study, the prevalence obtained from the patients’ records showed that 4% had
ILD. The median age, mean duration of disease, and follow-up time were significantly higher and longer in patients with ILD compared
to patients without (p < 0.05). Forced expiratory volume (FEV1), forced vital capacity (FVC), DLCO and total lung capacity (TLC)
were significantly lower in patients with ILD (p < 0.001). Patients with ILD had a significantly higher frequency of arthritis, serositis,
Raynaud’s phenomenon, myositis, and anti-Scl70 positivity (p = 0.01, 0.001, 0.02, 0.004, and 0.001, respectively). A significantly higher
number of patients had stopped using hydroxychloroquine (HCQ) in the ILD group (p = 0.04).
Conclusion: ILD is common in patients with SLE. Spirometry, diffusion tests, and CXR are simple but valuable tools to diagnose ILD in
patients with SLE. Considering the significant difference of prevalence between the start and the end of the study, one of the possibilities
is the underrecognition of SLE-associated interstitial pulmonary disease. The higher administration of immunosuppressives in these
patients may support a multisystemic active disease including the lungs.
Key words: SLE, interstitial lung disease, fibrosis, spirometry, carbon monoxide diffusion test

1. Introduction
Systemic lupus erythematosus (SLE) is a multisystemic
chronic autoimmune disease characterized by remissions
and exacerbations [1]. Pulmonary involvement develops
in up to 50% of patients during the course of SLE. As the
clinical presentation is often insignificant and nonspecific,
pulmonary involvement may be overlooked.
Clinically significant interstitial lung disease (ILD)
occurs in 1%-15% of patients with SLE. These patients
may present with an asymptomatic course or typically
present with exertional dyspnea and nonproductive
cough. The asymptomatic course demonstrates the
importance of pulmonary function tests and thoracic
imaging. In previous studies, long disease duration, late
onset disease, Raynaud’s phenomenon, anti-(U1) RNP

antibody positivity, sclerodactyly, and abnormal nail
capillary structure were determined as risk factors for the
development of ILD in SLE. High CRP, cryoglobulins,
hypocomplementemia and antinuclear antibody (ANA)
positivity were found to be associated with ILD in these
patients [2-5].
The diagnosis is based on a combination of clinical
features, imaging, histopathology and lung physiology.
Although lung biopsy is the gold standard method for
diagnosing ILD, it is usually not performed due to its
invasive nature. Nonspecific interstitial pneumonia (NSIP)
is the most common histological and radiologic pattern of
SLE-ILD whilst organizing pneumonia (OP), lymphoid
interstitial pneumonia (LIP), ordinary interstitial
pneumonia (UIP), desquamative interstitial pneumonia
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(DIP), and diffuse alveolar damage may also be seen. Highresolution lung tomography (HRCT), pulmonary function
test (PFT), and carbon monoxide diffusion test (DLCO)
can aid to diagnose ILD instead of invasive diagnostic
methods [3,4].
Herein, we aimed to assess the frequency of ILD in
patients with SLE followed up at a dedicated lupus clinic
and determine the associated risk factors.
2. Materials and methods
2.1. Participants
This study is conducted between January 2019 and January
2020. Three hundred patients were consequently chosen
from those followed up at the SLE/Antiphospholipid
syndrome (APS) outpatient clinic during their routine
follow-up dates.
All fulfilled the SLICC and ACR SLE classification
criteria [6]. Patient demographics, clinical and laboratory
characteristics, data regarding disease damage (SLICC/
SDI) and treatment histories were obtained from the
Rheumatology Department SLE/APS patient registry and
were revised. A special focus was given on the frequency of
interstitial lung disease defined by the presence of this data
on the database and the patient follow-up notes at the start
of the study. Subsequently, all patients were assigned to
undergo spirometric measurement and carbon monoxide
diffusion test.
Informed consent was obtained from all patients. The
study was approved by the İstanbul Faculty of Medicine
Ethics Committee with the number 2018/1758 and was
conducted in accordance with the standards specified in
the World Medical Association Helsinki Declaration.
2.2. Spirometric evaluation and carbon-monoxide
diffusion test
Spirometric measurements (FVC, FEV1, FEV1/FVC), total
lung capacity (TLC) measurements and diffusing capacity
of the lungs for carbon monoxide (DLCO) measurements
were performed in all subjects participating in the study
in accordance with the recommendations of the American
Thoracic Society and the European Respiratory Society [79]. The “single breath method” was used for TLC and DLCO
measurements. DLCO measurements were corrected for
serum hemoglobin (DLCO) [10]. FVC, FEV1, FEV1/FVC,
DLCO, and TLC values that were higher than 80% of the
healthy average were considered normal [11].
2.3. Diagnosis of interstitial lung diseases
Chest X-rays (CXR) performed within the last 6
months were evaluated. If no CXR was available in the
defined period of time, the patient underwent CXR.
If an undiagnosed patient had an unexplained low
FVC or DLCO and/or suspected findings on CXR, a
high resolution computed tomography (HRCT) was

performed. Images were evaluated independently by a
radiologist and a pulmonologist who were blinded to the
clinical parameters. After excluding other possible causes,
reticular and/or interstitial pattern, ground-glass opacity,
patchy consolidation, or honeycomb appearance were
assessed as ILD.
2.4. Statistical analysis
Normal distribution was assessed using KolmogorovSmirnov test. Differences of continuous variables between
groups were evaluated using t test or Mann-Whitney U
test. Categorical variables were compared using chi-square
tests. Statistical significance was accepted as p < 0.05.
Continuous variables were expressed as mean ± standard
deviation (SD) and categorical variables were expressed as
percentages (%). Analyses were performed using the SPSS
(SPSS version 22.0, IBM Corp., Armonk, New York, USA)
software.
3. Results
3.1. Demographic and clinical features
Three hundred patients with SLE followed up in the SLE/
APS outpatient clinic were evaluated. Eighty-eight percent
were female. The median age of the patients was 42 (19-76)
and the median age at the time of diagnosis was 30 (7-69).
The median duration of the disease and follow-up were 11
(1-39) and 10 (1-39) years, respectively. The demographic
and detailed clinical characteristics of the patients are
shown in table 1. According to the data obtained from the
database and patient follow-up notes before investigations
regarding ILD were started, the frequency of ILD in this
cohort was %4 (table 1).
Regarding treatment, 17% (n = 51) of the cohort had
stopped taking HCQ due to retinal toxicity. The mean
duration of HCQ use was 9.8 ± 6.8 (1-30) years. Fifty-five
percent of the patients (n = 165) had received azathioprine
treatment (mean duration of use 6.8 ± 4.8 [1-20] years);
46% (n = 137) mycophenolate mofetil (MMF) treatment
(mean duration 4.9 ± 3.4 [1-15] years); 43.3% (n = 130)
cyclophosphamide (mean cumulative dose 4.8 ± 2.8 [1-15]
g); 4.3% had received (n = 13) methotrexate and 17% (n =
51) had received rituximab (mean number of cycles 2.6 ±
1.7 [1-8]).
3.2. Spirometric measurement and carbon monoxide
diffusion test
The mean FVC value of the whole cohort was found as
96.1% (37-147), FEV1 as 92.9% (39-145), FEV1/FVC as
82.2% (60-105), DLCO as 80.9% (37-123), and TLC as
94.8% (50-127).
According to the results of chest X-ray (CXR) and
spirometric measurement/DLCO tests, 48 (16%) patients
were considered to have ILD. The mean FVC of patients
with ILD was 86% (50-126), FEV1 was 83.4% (47-125),
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Table 1. Clinical, laboratory, and demographic characteristics of
SLE patients.
SLE n = 300
Female, n (%)

265 (88.3)

Age (years) (mean ± SD, IQR)

43 ± 12.5 (19-76)

Age at diagnosis (years) (mean ± SD, IQR)

32 ± 12.2 (7-69)

Disease duration (years) (mean ± SD, IQR) 12.5 ± 8.3 (1-39)
Follow-up period (years) (mean ± SD, IQR) 11.5 ± 8.03 (1-39)
Clinical Features, n (%)
Photosensitivity

196 (65.3)

Alopecia

139 (46.3)

Malar rash

162 (54)

Discoid rash

23 (7.7)

Oral ulcer

32 (10.7)

Arthritis

227 (75.7)

Serositis (total)

82 (27.3)

Pericarditis

53 (17.7)

Pleuritis

54 (18)

Renal involvement

128 (42.7)

Hematological involvement (total)

219 (73)

Leukopenia

120 (40)

Lymphopenia

185 (61.7)

Thrombocytopenia

86 (28.7)

AIHA

78 (26)

Neurological involvement (total)

21 (7)

Seizure

13 (4.3)

Psychosis

8 (2.7)

Anti-dsDNA

242 (80.7)

ANA positivity

299 (99.7)

Anti-Sm

79 (26.3)

ACA IgG

50 (16.7)

ACA IgM

49 (16.3)

Lupus anticoagulant

68 (22.7)

Raynaud phenomenon

113 (37.7)

APS

65 (21.7)

Arterial thrombosis

43 (14.3)

Vein thrombosis

29 (9.7)

Livedo reticularis

53 (17.7)

Myositis

15 (5)

Interstitial lung disease*

12 (4)

Ischemic heart disease

6 (2)

Vasculitis

43 (14.3)

Anti-RNP

64 (21.3)

Anti-Ro

94 (31.3)
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Table 1. (Continued).

Anti-La

26 (8.7)

Scl-70

9 (3)

RF

20 (6.7)

Anti-CCP

8 (2.7)

ACA: Anticardiolipin antibody, AIHA: Autoimmune hemolytic
anemia, ANA: Antinuclear antibody, Anti-CCP: Anti cyclic
citrullinated peptide, Anti-RNP: Antiribonucleoprotein
antibodies, APS: Antiphospholipid syndrome, Anti-Sm:
Anti-Smith, RF: Rheumatoid factor, SLE: Systemic lupus
erythematosus.
*According to the data obtained from the database and patient
follow-up notes before investigations regarding ILD were started.

DLCO was 63.6% (37-89) and TLC was 82.9% (50-14.1).
Compared to patients without ILD, these values were
significantly lower (p < 0.001 for all comparisons) (Table
2).
3.3. Patients with ILD
In patients a showing restrictive pattern or/with lower
levels of DLCO, diagnosis of ILD was made by the
detection of interstitial appearance in posterior anterior
(PA) CXR or by thorax HRCT in the case of a suspicious
appearance in the PA CXR. Forty-eight patients were
identified to definitely have ILD with a dominance of
nonspecific interstitial pneumonia pattern followed
by usual interstitial pneumonia pattern in a very small
fraction of patients.
The comparison of SLE patients with (n = 48)
and without (n = 252) ILD in terms of demographic
characteristics are shown in Table 3. The median age,
mean disease, and follow-up time of SLE-ILD (+) patients
were significantly higher and longer than those of patients
without ILD (p = 0.003, 0.01, and 0.02, respectively).
The frequency of arthritis and serositis was significantly
higher in the SLE-ILD (+) group (89.6% vs 73, p = 0.01;
41.7% vs 24.6, p = 0.001 respectively). The frequency of
Raynaud’s phenomenon and the presence of myositis were
also significantly higher in the SLE-ILD (+) group (52.1%
vs 34.9, p = 0,02); 14.6% vs 3.2, p = 0.004, respectively).
Anti-Scl70 antibodies positivity rate was higher in the
group with SLE-ILD (+) (12.5% vs 1.2, p = 0.001).
The mean damage score of SLE-ILD (+) patients
was 2.8 ± 1.7, and 0.9 ± 1.3 in patients without ILD (p <
0.001). Neuropsychiatric damage (31.3% vs 8.7, p < 0.001),
avascular necrosis (22.9% vs 9.9, p = 0.02) and diabetes (16.7
vs 3.6, p = 0.002) were significantly higher in SLE-ILD (+)
patients. There was no significant difference between the
two groups in terms of renal and cardiovascular damage.
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During the follow-up period of SLE-ILD (+) patients, 4
patients (8 %) developed malignancy whilst 5 in (2%) SLEILD (–) were diagnosed with cancer (p = 0.04). Regarding
the types of malignancy, 1 had thyroid papillary cancer, 1
had breast cancer, 1 had severe dysplasia of the vocal cord
and 1 had diffuse large B-cell lymphoma. The frequency
of smokers in patients with ILD was significantly higher
compared to patients without (35.4% vs 15.8%, p = 0.002).
Comparison of treatment in both groups revealed that the
discontinuation rate of HCQ was higher in SLE-ILD (+)
group (27.1% vs 15.1, p = 0.04). There were no differences
in the frequencies of azathioprine, cyclophosphamide,
rituximab, and methotrexate use. However, the use of
MMF was significantly higher in the ILD (+) group (62.5%
vs 42.9, p = 0.01) (Table 4).

remarkable clinical symptoms, but can be silent or present
with a progressively symptomatic pattern as may be the
case with ILD [3]. Moreover, diagnosis may be shadowed
in the setting of a multisystemic active disease with a
noisy presentation leading to a shift in physician’s focus.
In this study, we aimed to determine the frequency and
characteristics of patients with ILD in a cohort of patients
with SLE and reveal the factors associated with it.
The frequency of ILD at the beginning of the study as
obtained from the database and the patient records and
frequency at the end of our study was remarkably different,
with a higher percentage in the latter (4% vs 16%).
Although the existence of a multisystemic active disease
leading the clinician to start a prompt treatment focusing
on vital organs with relatively easily noticed involvement
signs and the lack of sufficient investigations to diagnose
ILD may be explanations for this significant difference, it
is also important to consider the possible contribution of
drug effect to the occurrence of ILD.
Narvaez et al. in the Spanish multicenter
RELESSER cohort [12] published in 2018, reported
that pleuropulmonary involvement was associated with

4. Discussion
SLE is a chronic autoimmune disease with multisystemic
involvement, characterized by remissions and
exacerbations [1]. The frequency of lung disease in SLE
varies in different series with up to 50% of involvement
[3]. Pulmonary involvement may not always show up with

Table 2. Spirometry-DLCO characteristics of the SLE-ILD patient group.
Test

SLE-ILD (–)
(n=252)

SLE-ILD (+)
(n=48)

P value1

FVC% mean ± SD (min-max)

98 ± 15.3 (37-147)

86 ± 17.1 (50-126)

<0.001*

FEV1% mean ± SD (min-max)

94.7 ± 15.3 (39-145)

83.4 ± 17 (47-125)

<0.001*

FEV1/FVC mean ± SD (min-max)

82.3 ± 6.1 (60-105)

81.7 ± 4.7 (72-94)

0.4

DLCO% mean ± SD (min-max)

84.2 ± 12.2 (45-123)

63.6 ± 11.8 (37-89)

<0.001*

TLC% mean ± SD (min-max)

97.1 ± 12.7 (50-127)

82.9 ± 14.1 (54-108)

<0.001*

DLCO: Carbon monoxide diffusion capacity, FEV1: Forced expiratory volume at 1st s, FVC: Forced vital
capacity, ILD: Interstitial lung disease, max: Maximum, min: Minimum, mean: Average, SD: Standard
deviation, SLE: Systemic lupus erythematosus, TLC: Total Lung Capacity
1
Mann-Whitney U test
Table 3. Demographic characteristics of SLE-ILD (+) and ILD (–) groups.
Features

SLE-ILD (–)
(n = 252)

SLE-ILD (+)
(n = 48)

P value1

Gender, female n (%)

222 (88.1)

43 (89.6)

0.7

Age mean ± SD (min-max)

42 ± 12.2 (19-76)

48 ± 12.6 (25-71)

0.003*

Age at diagnosis mean ± SD (min-max)

31 ± 12 (7-69)

34 ± 13 (15-65)

0.19

Disease duration, years, mean ± SD (min-max)

11.9 ± 8 (1-39)

15.3 ± 9.3 (1-35)

0.01*

Follow-up period, year, mean ± SD (min-max)

11 ± 7.7 (1-39)

14.1 ± 8.8 (1-34)

0.02*

ILD: Interstitial lung disease, max: Maximum, min: Minimum, mean: Average, SD: Standard deviation, SLE:
Systemic lupus erythematosus.
1
Mann-Whitney U test.
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Table 4. Drug use in patients with and without SLE-ILD.
Features, n (%)

SLE-ILD (–)
(n = 252)

SLE-ILD (+)
(n = 48)

P value1

AZA

138 (54.8)

27 (56.3)

0.8

MMF

108 (42.9)

30 (62.5)

0.01*

CYC

103 (40.9)

27 (56.3)

0.05

HCQ discontinuation

38 (15.1)

13 (27.1)

0.04*

Rituximab

39 (15.5)

12 (25)

0.1

Methotrexate

11 (4.4)

2 (4.2)

1

AZA: Azathioprine, CYC: Cyclophosphamide, HCQ: Hydroxychloroquine,
ILD: Interstitial lung disease, MMF: Mycophenolate mofetil, SLE: Systemic
lupus erythematosus.
1
Pearson’s chi-square test.

long disease duration, advanced patient age, presence
of Raynaud’s phenomenon, and neuropsychiatric
involvement, as found similarly in our study. The frequency
of ILD in this cohort was 2.4% and the mean duration of
the disease up to the diagnosis of ILD was 7.7 years. These
patients were reported to have significantly lower survival.
Pulmonary involvement was found to be associated
with the presence of antiphospholipid antibodies,
severe nephritis, nonischemic heart disease, vasculitis,
hematological involvement, and anti-RNP antibodies.
Importantly a high SLEDAI score was positively correlated
with pleuropulmonary involvement in this cohort.
Haye Salinas et al. in the GLADEL cohort [13]
published in 2017 reported at least one pleuropulmonary
involvement in 421 patients (28.4%) of 1480 retrospective
SLE patients. The frequency of ILD was 1.4%, lower than
the rates reported in clinical studies and autopsy series and
an association was found with longer disease duration.
In a study published in 2002 by Nakano et al [14],
spirometry, PA CXR, and HRCT results of 110 patients
were retrospectively examined. As a result, DLCO
was found to be decreased in 52 patients (47%), and a
restrictive pattern was found in 9 patients (8%) as a result
of spirometric tests. The prevalence of pulmonary fibrosis
was found to be 13% and was correlated with the presence
of Raynaud’s phenomenon, similar to our study.
Significantly increased prevalence of Raynaud’s
phenomenon in ILD may be a warning sign for the
presence of ILD. The possibility of an overlap with systemic
sclerosis should also be considered in these patients.
Simple pulmonary function tests may give a clue for the
existence of ILD. However, as false negative test results
may also be the case, capillaroscopy and thoracic HRCT in
suspicious cases may be considered for an early diagnosis.
In the study published by Enomoto et al. in 2019
[15], 55 patients with a diagnosis of SLE-ILD were
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retrospectively examined and smoking was found to be
significant. Other parameters associated with SLE-ILD
were thrombocytopenia and high anti-ds DNA titers [15].
We also found that a significant proportion of patients
with ILD were smokers.
In our cohort, a small number of patients with ILD
were found to have myositis and/or anti-Scl-70 antibody
positivity. These patients all met the SLICC and ACR SLE
classification criteria, myositis specific antibodies were not
tested and none could be classified as systemic sclerosis
initially as none were known to have ILD before the study.
This may show the importance of a low threshold to
investigate ILD in patients with myositis and/or anti-Scl70
positivity even if there are no symptoms of pulmonary
disease.
Among patients with damage, the mean damage score
in patients with ILD was significantly higher compared to
patients without in our cohort. Regarding the comparison
of damaged items, the frequency of damage attributable
to glucocorticoids such as diabetes and avascular necrosis
was significantly higher in the ILD+ group. Despite the
lack of data on disease activity and cumulative steroid
dose, this finding may be interpreted as indirect support
for higher disease activity in patients with ILD requiring a
higher dose of glucocorticoids.
MMF use was significantly higher in our patients with
ILD. Since there is no data regarding the presence of ILD
at the initiation of MMF treatment, it is not possible to
establish a causal relationship between the drug and ILD
occurrence. On the other hand, ILD might be a part of
multisystemic involvement requiring MMF treatment, the
use of which might have prevented/delayed the emergence
of ILD symptoms and signs.
HCQ is an important immunomodulatory drug
licensed in the treatment of SLE and controls disease
activity. It has been shown to reduce damage and mortality
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in patients with SLE [16, 17]. We found that a higher
number of patients discontinued HCQ treatment due
primarily to retinal toxicity in the ILD+ group. Although
we do not know the exact time of onset for ILD, it is
possible to interpret this finding as the capability of HCQ
to prevent the development of ILD as the drug has many
beneficial effects. The threshold for drug discontinuation
should be kept high, and its continuation should be
encouraged unless toxicity is certainly proved.
The most important limitation of our study is the lack
of an inception cohort where it could be possible to detect
the first occurrence of ILD. Since a significant portion of
the patients were inactive or had low disease activity at the
time of the study, it is difficult to determine a relationship
with the disease activity and it is not possible to make a
definite judgment since the disease activity at the onset
of lung involvement is not known. Also important is to
consider the possible contribution of drug effect to the
occurrence of ILD. Since data before the onset of treatment
is lacking in most cases, this possible effect cannot be
shown.
5. Conclusion
In conclusion, considering the remarkable difference
of the frequency of ILD at the beginning and the end of
the study with a higher in the latter, we think that the
detection of the real incidence and prevalence of ILD will

ideally be possible by performing periodic screenings in
the follow up of patients with SLE starting from baseline.
In clinical practice, special consideration should be given
to diagnose ILD as it can be overlooked especially in the
case of a multisystemic active disease. Simple spirometryDLCO tests and PA CXR during the routine controls of
the patients will help to decide on the necessity of further
investigations.
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